Veeda Clinical Research Limited’s Post

Uncover the key aspects and register today for this exclusive webinar on Immunogenicity Risk Assessment for Innate Immune Response Modulating Impurities (IIRMI), hosted by our Biopharma expert, which promises an insightful exploration of key topics:   · Introduction to Immunogenicity and IIRMI & Importance of Immunogenicity Risk Assessment · Cell Models for IIRMI Assessment · USFDA Recommendations and Regulatory Landscape · Veeda Biopharma's Capabilities   Register for the webinar now - https://lnkd.in/dr63yhMR   Visit our page https://bit.ly/3TjEdpt to discover more about our Integrated Bioanalytical and Non-clinical Characterization Solutions. You can also write to us at info@veedacr.com to discuss your Biopharmaceutical needs. Chandrasekhar Koduru   Partners in creating a healthier tomorrow. #Veeda #VeedaCR #VeedaClinicalResearch #VeedaBiopharma #Webinar #Immunogenicity #Bioanalytical #Characterization

While bifunctional degraders were demonstrated at clinical stage for intracellular targets degraded by the proteasome (PROTACs), the company BioHaven demonstrated recently a small molecule bifunctional degrader acting on an extracellular target during a phase I trial. 💡 https://lnkd.in/dnRf-kym BHV-1300 degrades IgG antibodies, which account for 75% of all circulating antibodies, and is a promising treatment for the autoimmune disease rheumatoid arthritis. One moiety of BHV-1300 binds to IgG while the other moiety binds to asialoglycoprotein receptor (ASGPR) which is responsible for internalization into the lysosome and degradation. In addition to autoimmune diseases, this new category of small molecule degraders could also bring advantages for targeting neurodegenerative diseases, due to their ability to cross blood brain barrier more easily than antibodies. SEQENS, a leading CDMO for small molecule Active Pharmaceutical Ingredients 💊, proposes a specific development and manufacturing offer for bifunctional degraders, based on its combined expertise in complex multi step synthesis, oral bioavailability improvement and potent small molecules manufacturing. #degraders #pharmaceuticals #treatment

Here’s how we quantified the function of two Trastuzumab (anti-HER2) based antibody-drug conjugates (ADCs), and facilitated high-throughput analysis of dissociated cells with iQue®️ High-Throughput Screening (HTS) by Cytometry.   Find out how the ability to distinguish individual cell types within a mixture, can reveal mechanistic information on a drug’s activity. Learn more: https://ow.ly/2O6150RSZqu #highthroughputscreening #screening #highthroughput #antibodydrugconjugates #ADCs #spheroids #3Dcell #cytotoxicity

Thoughts on this? >> Dramatic new paths being taken in autoimmune diseases >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #competitivemarketing #pharmaceutical #biotech #pharma

Membrane proteins are at the forefront of drug discovery, shaping the effectiveness of medications. They play a pivotal role in various cellular processes and are linked to numerous human diseases. Did you know that over 60% of FDA-approved drugs target membrane proteins? Check out our website to learn more about our meticulously validated antibodies, targeting key membrane proteins like Claudin 18, c-MET, Androgen Receptor, and more. Learn how they contribute to the study and more precise targeting of challenging yet vital drug targets. Explore: https://ow.ly/V6IE50QpcMV #AntibodyOfTheMonth #MembraneProteins #DrugDiscovery

Happy New Year! 🎉 We wish you an enjoyable year of change! 🙌   Let us help you keep at least one of your New Year Resolutions by guiding you in the removal of in vivo virus assays in 2024. 2023 ended with a major regulatory update for Biopharmaceuticals: the adoption of the new ICH Q5A (R2) guideline on viral safety testing. The replacement of in vivo virus testing with NGS is now ‘encouraged’. 🧬   PathoQuest can help you make a difference in 2024 by removing in vivo based viral detection from your QC approach. 🐰   Our superior NGS assay is unique as it has been demonstrated to significantly outperform animal-based assays, saving you time and substantially reducing risk. 💯 Find out more about our alternatives to in vivo testing: https://lnkd.in/eiUuncs2 Any question/project? 📧 contact@pathoquest.com #ngs #biosafety #qualitycontrol #biotesting #CRO

Thoughts on this? >> Dramatic new paths being taken in autoimmune diseases >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #healthcare #pharma #pharmaceutical #biotech

Daprodustat (JESDUVROQ): The First HIF-PHD Inhibitor Approved for Anemia in the US | https://lnkd.in/gwhaXM7M GSK's daprodustat is the first HIF-prolyl hydroxylase domain (PHD) inhibitor approved for the treatment of anemia in chronic kidney disease (CKD) on dialysis in the US. PHDs have been attractive targets for treating anemia, especially in CKD patients, because the enzymes regulate levels of hypoxia-inducible factors (HIFs) including HIF-2, which induces the production of erythropoietin that in turn stimulates red blood cell production. This article highlights why HIF-PHDs are anemia targets, how daprodustat mimics the natural co-factor 2-oxoglutarate, and how the small molecule drug has similar safety and activity as epoetin alfa, an injected biologic. Article | https://lnkd.in/gwhaXM7M

Thoughts on this? >> Nurix’s protein degrader overcomes resistance to BTK mutations in small leukemia study >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharmaceutical #pharma #biotech

The variety of biologic treatments for psoriasis can make treatment selection challenging. In our latest study, we sought to bring some clarity to this decision-making process. By analyzing data from the Clalit database, we explored drug survival in psoriasis patients who switched from IL-23 inhibitors to IL-17 inhibitors. Want to see what we discovered? https://lnkd.in/g7cHYxkd